000120552 001__ 120552
000120552 005__ 20240228145452.0
000120552 0247_ $$2doi$$a10.1128/JVI.02030-16
000120552 0247_ $$2pmid$$apmid:28077642
000120552 0247_ $$2pmc$$apmc:PMC5331826
000120552 0247_ $$2ISSN$$a0022-538X
000120552 0247_ $$2ISSN$$a1098-5514
000120552 0247_ $$2altmetric$$aaltmetric:16865757
000120552 037__ $$aDKFZ-2017-00981
000120552 041__ $$aeng
000120552 082__ $$a570
000120552 1001_ $$0P:(DE-HGF)0$$aVragniau, Charles$$b0
000120552 245__ $$aStudies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
000120552 260__ $$aBaltimore, Md.$$bSoc.$$c2017
000120552 3367_ $$2DRIVER$$aarticle
000120552 3367_ $$2DataCite$$aOutput Types/Journal article
000120552 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511259034_9899
000120552 3367_ $$2BibTeX$$aARTICLE
000120552 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120552 3367_ $$00$$2EndNote$$aJournal Article
000120552 520__ $$aDefensins are small antimicrobial peptides capable of neutralizing human adenovirus (HAdV) in vitro by binding capsid proteins and blocking endosomal escape of virus. In humans, the alpha defensin HD5 is produced by specialized epithelial cells of the gastrointestinal and genito-urinary tracts. Here, we demonstrate, using patient biopsy specimens, that HD5 is also expressed as an active, secreted peptide by epithelial ovarian and lung cancer cells in situ This finding prompted us to study the role of HD5 in infection and spread of replication-competent, oncolytic HAdV type 3 (HAdV3). HAdV3 produces large amounts of penton-dodecahedra (PtDd), virus-like particles, during replication. We have previously shown that PtDd are involved in opening epithelial junctions, thus facilitating lateral spread of de novo-produced virions. Here, we describe a second function of PtDd, namely, the blocking of HD5. A central tool to prove that viral PtDd neutralize HD5 and support spread of progeny virus was an HAdV3 mutant virus in which formation of PtDd was disabled (mut-Ad3GFP, where GFP is green fluorescent protein). We demonstrated that viral spread of mut-Ad3GFP was blocked by synthetic HD5 whereas that of the wild-type (wt) form (wt-Ad3GFP) was only minimally impacted. In human colon cancer Caco-2 cells, induction of cellular HD5 expression by fibroblast growth factor 9 (FGF9) significantly inhibited viral spread and progeny virus production of mut-Ad3GFP but not of wt-Ad3GFP. Finally, the ectopic expression of HD5 in tumor cells diminished the in vivo oncolytic activity of mut-Ad3GFP but not of wt-Ad3GFP. These data suggest a new mechanism of HAdV3 to overcome innate antiviral host responses. Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it has been reported that human defensin HD5 inactivates specific human adenoviruses by binding to capsid proteins and blocking endosomal escape of virus. The central new findings described in our manuscript are the following: (i) the discovery of a new mechanism used by human adenovirus serotype 3 to overcome innate antiviral host responses that is based on the capacity of HAdV3 to produce subviral penton-dodecahedral particles that act as decoys for HD5, thus preventing the inactivation of virus progeny produced upon replication; (ii) the demonstration that ectopic HD5 expression in cancer cells decreases the oncolytic efficacy of a serotype 5-based adenovirus vector; and (iii) the demonstration that epithelial ovarian and lung cancers express HD5. The study improves our understanding of how adenoviruses establish infection in epithelial tissues and has implications for cancer therapy with oncolytic adenoviruses.
000120552 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000120552 588__ $$aDataset connected to CrossRef, PubMed,
000120552 650_7 $$2NLM Chemicals$$aalpha-Defensins
000120552 650_7 $$2NLM Chemicals$$aalpha-defensin 5, human
000120552 7001_ $$0P:(DE-He78)a8c698e0904394407c5261932915daa5$$aHübner, Jens-Martin$$b1$$udkfz
000120552 7001_ $$aBeidler, Peter$$b2
000120552 7001_ $$aGil, Sucheol$$b3
000120552 7001_ $$aSaydaminova, Kamola$$b4
000120552 7001_ $$aLu, Zhuo-Zhuang$$b5
000120552 7001_ $$aYumul, Roma$$b6
000120552 7001_ $$aWang, Hongjie$$b7
000120552 7001_ $$aRichter, Maximilian$$b8
000120552 7001_ $$aSova, Pavel$$b9
000120552 7001_ $$aDrescher, Charles$$b10
000120552 7001_ $$aFender, Pascal$$b11
000120552 7001_ $$aLieber, André$$b12
000120552 773__ $$0PERI:(DE-600)1495529-5$$a10.1128/JVI.02030-16$$gVol. 91, no. 6, p. e02030-16 -$$n6$$pe02030-16 -$$tJournal of virology$$v91$$x1098-5514$$y2017
000120552 909CO $$ooai:inrepo02.dkfz.de:120552$$pVDB
000120552 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8c698e0904394407c5261932915daa5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000120552 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000120552 9141_ $$y2017
000120552 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ VIROL : 2015
000120552 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120552 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120552 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120552 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120552 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120552 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120552 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000120552 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120552 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120552 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000120552 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120552 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120552 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000120552 980__ $$ajournal
000120552 980__ $$aVDB
000120552 980__ $$aI:(DE-He78)B062-20160331
000120552 980__ $$aUNRESTRICTED